The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies-Reference-Cited by-全球学者库

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

Published:2006-06 Issue:6 Volume:9 Page:485-495
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Ji Hongbin,Li Danan,Chen Liang,Shimamura Takeshi,Kobayashi Susumu,McNamara Kate,Mahmood Umar,Mitchell Albert,Sun Yangping,Al-Hashem Ruqayyah,Chirieac Lucian R.,Padera Robert,Bronson Roderick T.,Kim William,Jänne Pasi A.,Shapiro Geoffrey I.,Tenen Daniel,Johnson Bruce E.,Weissleder Ralph,Sharpless Norman E.,Wong Kwok-Kin

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference45 articles.

1. Targeting multiple signal transduction pathways in lung cancer;Adjei;Clin. Lung Cancer,2005

2. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer;Amann;Cancer Res.,2005

3. ErbB-targeted therapeutic approaches in human cancer;Arteaga;Exp. Cell Res.,2003

4. Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers;Blagosklonny;Cancer Biol. Ther.,2004

5. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer;Cappuzzo;J. Natl. Cancer Inst.,2005

Cited by 391 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The correlation between pre-treatment CEA levels and the EGFR mutation status in advanced lung adenocarcinoma;Journal of Cancer Research and Therapeutics;2024-01-22

2. The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance;Nature Genetics;2023-12-04

3. Molecular pathology of non‐small cell carcinoma;Histopathology;2023-11-07

4. Preclinical Modeling of Pathway-Targeted Therapy of Human Lung Cancer in the Mouse;Cold Spring Harbor Perspectives in Medicine;2023-10-03

5. EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugates;Translational Lung Cancer Research;2023-07